R. Donahue

发表

A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas

T. Olencki, G. Lesinski, J. Schlom, 2016, Cancer Immunology, Immunotherapy.

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

J. Schlom, R. Madan, J. Gulley, 2017, Journal of Immunotherapy for Cancer.

PATHWAYS TARGETED BY THE OGF-OGFr AXIS ARE DETERMINANTS IN THE PROGRESSION OF HUMAN OVARIAN CANCER

R. Donahue, 2011 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

J. Schlom, S. Rabizadeh, P. Soon-Shiong, 2020, Journal for immunotherapy of cancer.

Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function

I. Zagon, P. McLaughlin, M. Rogosnitzky, 2008, Experimental biology and medicine.

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

Andressa Ardiani, R. Donahue, J. Hodge, 2014, Oncotarget.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

M. Brechbiel, J. Schlom, R. Madan, 2016, Oncotarget.

Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic

J. Schlom, M. Goswami, J. Marté, 2021, Journal for ImmunoTherapy of Cancer.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

K. Kelly, R. Valicenti, S. Stewart, 2018, International journal of radiation oncology, biology, physics.

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

J. Schlom, R. Madan, J. Marté, 2019, Clinical Cancer Research.

Phase I Trial of a Modified Vaccinia Ankara Priming Vaccine Followed by a Fowlpox Virus Boosting Vaccine Modified to Express Brachyury and Costimulatory Molecules in Advanced Solid Tumors.

J. Schlom, R. Madan, Marijo Bilusic, 2019, The oncologist.

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer.

S. Steinberg, J. Marshall, J. Schlom, 2022, The oncologist.

Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

A. Mammen, S. Pittaluga, S. Hewitt, 2019, Journal of Immunotherapy for Cancer.

Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis

I. Zagon, P. McLaughlin, D. Goldenberg, 2009, BMC Cancer.

The Opioid Growth Factor Inhibits Established Ovarian Cancer in Nude Mice and Can Be Combined with Taxol or Cisplatin to Enhance Growth Inhibition

I. Zagon, P. McLaughlin, R. Donahue, 2011 .

Overexpression of OGFr Downregulates Ovarian Cancer Cell Proliferation in Vitro and Inhibits Tumorigenesis

I. Zagon, P. McLaughlin, R. Donahue, 2011 .

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

J. Schlom, R. Madan, W. Dahut, 2015, Cancer Immunology Research.

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

H. Parnes, P. Pinto, J. Schlom, 2018, European urology focus.

Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets

M. Merino, P. Pinto, J. Schlom, 2014, International journal of cancer.

Contrasting autoimmune and treatment effects reveals baseline set points of immune toxicity following checkpoint inhibitor treatment

J. Schlom, J. Tsang, A. Martins, 2022, bioRxiv.

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

F. Guadagni, J. Schlom, A. Spila, 2013, Oncoimmunology.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

J. Schlom, R. Madan, J. Marté, 2018, Clinical Cancer Research.

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

Zhigang, Kang, J. Schlom, 2017 .

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

S. Salas, J. Schlom, B. Cho, 2020, Journal for ImmunoTherapy of Cancer.

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

S. Steinberg, I. Pastan, D. Venzon, 2022, Cancer medicine.

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

K. Tsang, R. Donahue, J. Hodge, 2015, Cancer cell & microenvironment.

Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer

I. Zagon, P. McLaughlin, R. Donahue, 2013, Experimental biology and medicine.

Immune Consequences of Decreasing Tumor Vasculature with Antiangiogenic Tyrosine Kinase Inhibitors in Combination with Therapeutic Vaccines

A. Molinolo, R. Donahue, J. Hodge, 2014, Cancer Immunology Research.

First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors

J. Schlom, R. Madan, Marijo Bilusic, 2018, Clinical Cancer Research.

A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.

C. Kiritsy, T. Fry, J. Lai, 2014, Vaccine.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

R. Donahue, J. Hodge, I. Grenga, 2015, Journal of Immunotherapy for Cancer.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

A. Mammen, J. Schlom, T. Lehky, 2018, Annals of the rheumatic diseases.

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

J. Schlom, R. Madan, Marijo Bilusic, 2021, Journal for ImmunoTherapy of Cancer.

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

S. Steinberg, J. Schlom, R. Madan, 2019, The oncologist.

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

S. Steinberg, J. Schlom, W. Figg, 2021, Journal for ImmunoTherapy of Cancer.

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa

D. Venzon, J. Schlom, J. Gulley, 2022, Journal for ImmunoTherapy of Cancer.

A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.

H. Parnes, P. Pinto, J. Schlom, 2022, European urology focus.

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

S. Steinberg, J. Schlom, S. Lipkowitz, 2021, Frontiers in Oncology.

Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12.

J. Schlom, J. Gulley, R. Donahue, 2023, International immunopharmacology.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

J. Schlom, Karin M. Knudson, C. Allen, 2018, Oncoimmunology.

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.

I. Zagon, P. McLaughlin, R. Donahue, 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

J. Schlom, R. Donahue, Jacob Richards, 2016, Clinical & translational immunology.

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.

J. Schlom, J. Gulley, A. Rajan, 2022, The oncologist.

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

S. Steinberg, P. Choyke, S. Harmon, 2020, Journal for ImmunoTherapy of Cancer.

Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy

J. Schlom, P. Kim, J. Gulley, 2014, The Journal of Immunology.

Combination Immunotherapy Lymphocytes: A Rationale for Its Use in Lymphocytes while Preserving Effector T Decreases Human T Regulatory Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax),

J. Schlom, J. Gulley, C. Jochems, 2014 .

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

P. Meltzer, S. Steinberg, M. Merino, 2018, Journal of Immunotherapy for Cancer.

Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.

J. Schlom, R. Madan, Marijo Bilusic, 2021 .

Abstract 4901: Short-course enzalutamide reveals immune activating properties in patients with biochemically recurrent prostate cancer

J. Schlom, R. Madan, J. Gulley, 2016 .

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

J. Schlom, R. Madan, Marijo Bilusic, 2019, Journal of Immunotherapy for Cancer.

OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)

A. Mammen, S. Pittaluga, J. Schlom, 2017 .

Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

J. Schlom, R. Madan, Marijo Bilusic, 2018 .

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

J. Schlom, J. Gulley, C. Jochems, 2020, Journal for ImmunoTherapy of Cancer.

T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.

I. Zagon, P. McLaughlin, R. H. Bonneau, 2011, Immunobiology.

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

Walter M. Stadler, Christopher R. Heery, James L. Gulley, 2016, Oncotarget.

Docetaxel Alone or in CombinationWith a Therapeutic Cancer Vaccine ( PANVAC ) in PatientsWithMetastatic Breast Cancer A Randomized Clinical Trial

S. Steinberg, N. Ibrahim, J. Murray, 2015 .

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

Christopher R. Heery, James L. Gulley, Jacob Richards, 2016, Journal of circulating biomarkers.

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer

J. Schlom, B. Korchin, B. Widemann, 2021, Journal for ImmunoTherapy of Cancer.

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma

Deric M. Park, S. Steinberg, M. Gilbert, 2021, The oncologist.

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer

M. Bernstein, R. Donahue, J. Hodge, 2012, Front. Oncol..

Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.

J. Schlom, M. Roselli, Marijo Bilusic, 2017, Urologic oncology.

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Andressa Ardiani, R. Donahue, J. Hodge, 2014, Journal of Translational Medicine.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.

I. Zagon, P. McLaughlin, R. Donahue, 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury

J. Schlom, R. Madan, W. Dahut, 2017, Clinical Cancer Research.

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

N. Ibrahim, J. Schlom, R. Madan, 2016, Cancer Immunology Research.

Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

S. Steinberg, N. Ibrahim, J. Murray, 2015, JAMA oncology.

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.

J. Schlom, R. Madan, Marijo Bilusic, 2023, The oncologist.

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

M. Merino, J. Schlom, A. Gramza, 2020, Frontiers in Endocrinology.

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

J. Schlom, J. Friedman, J. Gulley, 2021, Journal for ImmunoTherapy of Cancer.

Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer

J. Schlom, B. Korchin, J. Gray, 2022, International journal of cancer.

Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer

I. Zagon, P. McLaughlin, R. Donahue, 2012, Experimental biology and medicine.

Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis.

I. Zagon, P. McLaughlin, R. Donahue, 2010, Investigative ophthalmology & visual science.

Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model

I. Zagon, P. McLaughlin, R. Donahue, 2011, Experimental biology and medicine.

The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.

I. Zagon, P. McLaughlin, R. Donahue, 2011, Gynecologic oncology.

Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin

I. Zagon, P. McLaughlin, R. Donahue, 2011, Experimental biology and medicine.

Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.

I. Zagon, P. McLaughlin, R. Donahue, 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management

J. Schlom, J. Marté, J. Gulley, 2020, Journal for ImmunoTherapy of Cancer.

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients

J. Schlom, R. Madan, J. Gulley, 2014, Journal of Immunotherapy for Cancer.

IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL: MP15‐10

T. Jang, J. Schlom, R. Weiss, 2017 .

Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.

J. Schlom, R. Madan, J. Marté, 2015 .

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.

E. Plimack, J. Schlom, W. Figg, 2023, The oncologist.

Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.

J. Schlom, R. Madan, J. Marté, 2022, Journal of Clinical Oncology.

Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation.

P. Choyke, P. Pinto, B. Turkbey, 2017 .

Abstract OT1-08-01: A phase Ib trial of sequential combinations of BN-brachyury, entinostat, ado-trastuzumab emtansine (T-DM1) and bintrafusp alfa (M7824) in advanced stage breast cancer (BrEAsT)

S. Steinberg, J. Schlom, S. Lipkowitz, 2020 .

Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.

I. Zagon, P. McLaughlin, J. Fanning, 2012, Gynecologic oncology.

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.

I. Zagon, P. McLaughlin, R. H. Bonneau, 2011, Immunobiology.

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses

J. Schlom, R. Madan, J. Gulley, 2015, Journal of Immunotherapy for Cancer.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

K. Kelly, R. Valicenti, S. Stewart, 2018, International Journal of Radiation Oncology, Biology, Physics.

A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination with standard of care definitive radiotherapy in locally advanced, unresectable, chordoma.

Deric M. Park, S. Steinberg, M. Gilbert, 2020 .

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023, Journal for ImmunoTherapy of Cancer.

Digital Commons@Becker Digital

F. Saad, A. Ravaud, A. Armstrong, 2023 .

The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19

J. Schlom, R. Donahue, 2020, The Journal of infectious diseases.

Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies

A. Rolfe, S. Salas, J. Schlom, 2019, Clinical Trials.

Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies

J. Schlom, M. Goswami, R. Donahue, 2023, Oncotarget.

PD-L1 and MHC-I expression in 19 human tumor cell lines and modulation by interferon-gamma treatment

J. Schlom, R. Donahue, Lauren M. Lepone, 2014, Journal of Immunotherapy for Cancer.

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

E. Plimack, J. Schlom, E. Ross, 2022, Prostate Cancer and Prostatic Diseases.

Digital Commons@Becker Digital

A. Ravaud, Y. Vugmeyster, M. Sznol, 2023 .

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

J. Schlom, A. Heydebreck, R. Madan, 2017, The Lancet. Oncology.

Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors

R. Donahue, N. Toney, Jeffrey Schlom, 2023, Journal of Experimental & Clinical Cancer Research.

438 Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs)

J. Schlom, J. Gulley, A. Rajan, 2022, Regular and Young Investigator Award Abstracts.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Effects of tyrosine kinase inhibitors alone or in combination with vaccine on tumor-infiltrating myeloid cells

J. Schlom, R. Donahue, I. Grenga, 2013, Journal of Immunotherapy for Cancer.

Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.

I. Zagon, P. McLaughlin, R. Donahue, 2009, American journal of physiology. Regulatory, integrative and comparative physiology.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

K. Kelly, R. Valicenti, S. Stewart, 2018, International journal of radiation oncology, biology, physics.

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

Gurkan Guntas, R. Donahue, Y. Tsai, 2023, Science Translational Medicine.

Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.

I. Zagon, P. McLaughlin, J. Fanning, 2012, Gynecologic oncology.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2023, medRxiv.

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

Chiu-Hsieh Hsu, H. Parnes, J. Schlom, 2022, Journal of Clinical Oncology.

Abstract 628: Pan-Bcl-2 inhibitor, GX15-070 (Obatoclax), decreases human T regulatory lymphocytes while preserving effector T Lymphocytes: A rationale for its use in combination immunotherapy

J. Schlom, P. Kim, J. Gulley, 2014 .